白细胞介素-4和γ-干扰素基因联合治疗胶质瘤

目的 探讨逆转录病毒载体介导的白细胞介素(IL)-4和γ-干扰素(IFN)基因联合治疗胶质瘤的作用。方法构建携带IL-4或IFN-γ基因的逆转录病毒载体，将其导入逆转录病毒包装细胞；将携带IL-4和IFN-γ基因的逆转录病毒包装细胞分别或联合注射到脑内荷瘤大鼠的肿瘤组织中，观察其治疗作用。结果成功获得携带治疗基因的逆转录病毒包装细胞PA317IFN-γ和PA317IL-4，所产病毒滴度分别为2x10^6cfu／ml和2．5x10^6cfu／ml。包装细胞瘤内注射能够诱导大鼠产生抗肿瘤免疫反应，杀伤肿瘤细胞，联合应用具有协同治疗作用。结论携带IL-4或IFN-γ基因的逆转录病毒包装细胞瘤内注射是一种有效的胶质瘤基因治疗方法，两者联合应用具有协同治疗作用。     

体细胞基因治疗及其在口腔医学中应用前景

转基因治疗是近年来引人注目的新领域,发展十分迅速。本文对体细胞转基因治疗基本概念、技术问题及研究状况进行了论述,同时对基因治疗在口腔医学中应用前景作了综述。     

腺病毒介导的B7—1基因转移对小鼠肝癌成瘤性的影响

腺病毒介导的Ｂ７－１基因转移对小鼠肝癌成瘤性的影响黄洪莲王小宁钱其军沈峰谢天培施乐华陈汉吴孟超郭亚军肿瘤免疫基因治疗的主要目的之一是诱导具有杀伤活性的肿瘤特异性Ｔ淋巴细胞，增强其抗肿瘤排斥反应。许多肿瘤都存在肿瘤抗原或肿瘤相关抗原，但缺乏Ｔ细胞激活所...     

Adenovirus-mediated human β-nerve growth factor gene transfer has a protective effect on cochlear spiral ganglion after blast exposure

Objective：To study whether adenovirus-mediated human β-nerve growth factor （Ad-hNGFβ） gene has any protective effect on blast hearing impairment. Methods：Deafness was induced by blast exposure （172.0 dB） in 30 healthy guinea pigs. On day 7 of blast exposure, Ad-hNGFβ was infused into the perilymphatic space of 20 animals as the study group （hNGFβ group）, and artificial perilymph fluid （APF） was infused into the perilymphatic space of the other 10 animals as the control group. At weeks 1, 4 and 8 after blast exposure, the animals were sacrificed and the cochleae were removed for immunohistochemical and HE stainings. Results： Expression of Ad-hNGFβ protein was detected in each turn of the cochlea at the 1st week, with almost equal intensity in all turns. At the 4th week, the reactive intensity of the expression of Ad-hNGFβ protein decreased. At the 8th week, no expression was detectable. The results of HE staining showed that the amount of spiral ganglions in hNGFβ group was significantly greater than that of the control group at week 4 （P〈0.01）. Conclusion： Ad-hNGFβ can be expressed at a high level and for a relatively long period in the blast impaired cochlea, suggesting that Ad-hNGFβ has a protective effect on cochlear spiral ganglion cells after blast exposure and the efficient gene transfer into cochlea had been achieved without toxicity.     

EFFECTS OF p53 GENE THERAPY COMBINED WITH CYCLOOXYGENASE-2 INHIBITOR ON CYCLOOXYGENASE-2 GENE EXPRESSION AND GROWTH INHIBITION OF HUMAN LUNG CANCER CELLS

Background Gene therapy by adenovirus-mediated wild-type p53 gene transfer has been shown to inhibit lung cancer growth in vitro, in animal models, and in human clinical trials. The antitumor effect of selective cyclooxygenase （COX）-2 inhibitors has been demonstrated in preclinical studies. However, no information is available on the effects of p53 gene therapy combined with selective COX-2 inhibitor on COX-2 gene expression and growth inhibition of human lung cancer cells. Methods We evaluated the effects of recombinant adenovirus-p53 （Adp53） gene therapy combined with selective CADX-2 inhibitor on the proliferation, apoptosis, cell cycle arrest of human lung adenocarcinoma A549 cell line, and the effects of tumor suppressor exogenous wild type p53 on COX-2 gene expression. Results Ad-p53 gene therapy combined with selective COX-2 inhibitor celecoxib shows significant synergistic inhibition effects on the growth of human lung adenocarcinoma A549 cell line. Exogenous p53 gene can suppress COX-2 gene expression. Conclusions Significant synergistic inhibition effects of A549 cell line by the combined Ad-p53 and selective COX-2 inhibitor celecoxib may be achieved by enhancement of growth inhibition, apoptosis induction and suppression of COX-2 gene expression. This study provides first evidence that the administration of p53 gene therapy in combination with COX-2 inhibitors might be a new clinical strategy for the treatment or prevention of NSCLC.     

展望21世纪早期的普外科

现在，普外科正处于一个飞跃发展的时期，跨入２１世纪后，更会有新的成就。仅就管见所及，在此作一些“不成图像”的素描，待以后的现实，作自然的修改。１以手术为主与非手术治疗组成的综合性治疗取代单纯依靠“一把刀”，成为普外科主要治疗的观点日占上风外科是以手术...     

IL—6基因转染的瘤苗体内诱导的抗肿瘤免疫功能与效果

经丝裂霉素C体外处理后,将IL-6基因转染的、高分泌的IL-6的B16黑色素瘤细胞制成瘤苗。结果发现,体内注射IL-6基因转染的瘤苗后,小鼠脾脏CTL活性、NK活性及IL-2诱导的LAK活性显著升高。经IL-6基因转染瘤苗体内治疗后,荷瘤小鼠的皮下肿瘤生长显著减慢、肺转移结节数显著降低、存活期显著延长,若同时合用低剂量IL-2,则上述治疗效果更好。可见IL-6基因转染的瘤苗能有效地通过诱导机体抗肿瘤免疫功能而发挥抗肿瘤作用,与低剂量IL-2合用后,IL-6基因转染的瘤苗的抗肿瘤效果更佳。     

胶质瘤的免疫基因治疗

胶质瘤是颅内常见肿瘤，多数患者预后不佳，肿瘤免疫基因治疗是基因 治疗的研究热点之一，有些治疗方案已进入临床试用阶段，包括细胞因子基因治疗，肿瘤抗原靶向的基因治疗，共刺激分子基因治疗，MHC靶向的基因治疗及反义基因治疗等。